.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
US Department of Justice
Deloitte
Healthtrust
Dow
Citi
McKinsey
Chinese Patent Office
Federal Trade Commission
Medtronic

Generated: June 23, 2017

DrugPatentWatch Database Preview

Fluticasone furoate; vilanterol trifenatate - Generic Drug Details

« Back to Dashboard

What are the generic sources for fluticasone furoate; vilanterol trifenatate and what is the scope of fluticasone furoate; vilanterol trifenatate freedom to operate?

Fluticasone furoate; vilanterol trifenatate
is the generic ingredient in one branded drug marketed by Glaxo Grp Ltd and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone furoate; vilanterol trifenatate has three hundred and forty-two patent family members in forty-two countries.

There are twenty-two drug master file entries for fluticasone furoate; vilanterol trifenatate. One supplier is listed for this compound.

Summary for Generic Name: fluticasone furoate; vilanterol trifenatate

Tradenames:1
Patents:15
Applicants:1
NDAs:1
Drug Master File Entries: see list22
Suppliers / Packagers: see list1
Clinical Trials: see list593
Drug Prices:see low prices
DailyMed Link:fluticasone furoate; vilanterol trifenatate at DailyMed

Pharmacology for Ingredient: fluticasone furoate; vilanterol trifenatate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes7,629,335► SubscribeY ► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes6,878,698► Subscribe ► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes8,511,304► SubscribeY ► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes7,101,866► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fluticasone furoate; vilanterol trifenatate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 20135,873,360► Subscribe
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 20155,873,360► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fluticasone furoate; vilanterol trifenatate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,361,787Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
6,858,596 Formulation containing anti-inflammatory androstane derivative► Subscribe
7,125,985Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,750,210 Formulation containing novel anti-inflammatory androstane derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluticasone furoate; vilanterol trifenatate

Country Document Number Estimated Expiration
Poland359999► Subscribe
Japan2005533583► Subscribe
Russian Federation2312854► Subscribe
Argentina058289► Subscribe
Hungary230328► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140013 00103Estonia► SubscribePRODUCT NAME: VILANTEROOLTRIFENATAAT;REG NO/DATE: K(2013)8089 (LOPLIK) 13.11.2013
2014019,C1425001Lithuania► SubscribePRODUCT NAME: VILANTEROLUM; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
00664Netherlands► SubscribePRODUCT NAME: VILANTEROL, DAN WEL EEN ZOUT OF SOLVAAT DAARVAN, IN HET BIJZONDER HET TRIFENYLACETAATZOUT; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
14/024Ireland► SubscribePRODUCT NAME: VILANTEROL OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Julphar
Cerilliant
Chubb
Accenture
Johnson and Johnson
Federal Trade Commission
McKinsey
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot